1）Rindi G, Falconi M, Klersy C, et al：TNM staging of neoplasms of the endocrine pancreas：results from a large international cohort study. J Natl Cancer Inst 104：764-777, 2012
2）Falconi M, Bartsch DK, Eriksson B, et al：ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system：well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95：120-134, 2012
3）Sarmiento JM, Farnell MB, Que FG, et al：Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas：long-term survival analysis. World J Surg 26：1267-1271, 2002
4）Elias D, Lasser P, Ducreux M, et al：Liver resection （and associated extrahepatic resections） for metastatic well-differentiated endocrine tumors：a 15-year single center prospective study. Surgery 133：375-382, 2003
5）Glazer ES, Tseng JF, Al-Refaie W, et al：Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB（Oxford）12：427-433, 2010
6）Saxena A, Chua TC, Sarkar A, et al：Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms （NENs） supports an aggressive surgical approach. Surgery 149：209-220, 2011
7）Pascher A, Steinmuller T, Radke C, et al：Primary and secondary hepatic manifestation of neuroendocrine tumors. Langenbecks Arch Surg 385：265-270, 2000
8）Scigliano S, Lebtahi R, Maire F, et al：Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases：a 15-year monocentric experience. Endocr Relat Cancer 16：977-990, 2009
9）Gomez D, Malik HZ, Al-Mukthar A, et al：Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours：outcome and prognostic predictors. HPB （Oxford） 9：345-351, 2007
10）Touzios JG, Kiely JM, Pitt SC, et al：Neuroendocrine hepatic metastases：does aggressive management improve survival? Ann Surg 241：776-783；discussion 783-775, 2005
11）Cho CS, Labow DM, Tang L, et al：Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 113：126-134, 2008
12）Mayo SC, de Jong MC, Pulitano C, et al：Surgical management of hepatic neuroendocrine tumor metastasis：results from an international multi-institutional analysis. Ann Surg Oncol 17：3129-3136, 2010
13）Chamberlain RS, Canes D, Brown KT, et al：Hepatic neuroendocrine metastases：does intervention alter outcomes? J Am Coll Surg 190：432-445, 2000
14）Sarmiento JM, Heywood G, Rubin J, et al：Surgical treatment of neuroendocrine metastases to the liver：a plea for resection to increase survival. J Am Coll Surg 197：29-37, 2003
15）Frilling A, Li J, Malamutmann E, et al：Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96：175-184, 2009
16）Ito T, Okusaka T, Ikeda M, et al：Everolimus for advanced pancreatic neuroendocrine tumours：a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 42：903-911, 2012
17）Ito T, Okusaka T, Nishida T, et al：Phase Ⅱ study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31：1265-1274, 2013
18）Moertel CG, Lefkopoulo M, Lipsitz S, et al：Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326：519-523, 1992
19）Rivera E, Ajani JA：Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21：36-38, 1998
20）Kouvaraki MA, Ajani JA, Hoff P, et al：Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22：4762-4771, 2004
21）Kulke MH, Stuart K, Enzinger PC, et al：Phase Ⅱ study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24：401-406, 2006
22）Strosberg JR, Fine RL, Choi J, et al：First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117：268-275, 2011
23）Devata S, Kim EJ：Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. Case Rep Oncol 5：622-626, 2012
24）Hodul PJ, Strosberg JR, Kvols LK：Aggressive surgical resection in the management of pancreatic neuroendocrine tumors：when is it indicated? Cancer Control 15：314-321, 2008
25）Sorbye H, Westre B, Horn A：Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. Eur J Surg Oncol 33：1209-1210, 2007
26）Frilling A, Clift AK：Therapeutic strategies for neuroendocrine liver metastases. Cancer 121：1172-1186, 2015
27）Kaemmerer D, Prasad V, Daffner W, et al：Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15：5867-5870, 2009
28）Sowa-Staszczak A, Pach D, Chrzan R, et al：Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours（NETs）. Eur J Nucl Med Mol Imaging 38：1669-1674, 2011
Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395：185-192, 2010
Y-DOTA-lanreotide as effective palliative therapy. Radiology 237：718-726, 2005
31）Kratochwil C, Lopez-Benitez R, Mier W, et al：Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer 18：595-602, 2011
Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38：302-311, 2011
ログイン
ランキング
お知らせ
ログイン
